MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukaemia but can be preferentially targeted by the MDM2 inhibitor Nutlin-3a

I Tinhofer; I Gryshchenko; M Stoecher; Sebastian Hofbauer; PT Daniel; Richard Greil

doi:10.1016/S1359-6349(07)71298-3

MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukaemia but can be preferentially targeted by the MDM2 inhibitor Nutlin-3a

I Tinhofer, I Gryshchenko, M Stoecher, Sebastian Hofbauer, PT Daniel, Richard Greil

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Pages (from-to)	347-347
Journal	ECJ SUPPLEMENTS
Volume	5
Issue number	4
DOIs	https://doi.org/10.1016/S1359-6349(07)71298-3
Publication status	Published - 2007
Event	14th European Cancer Conference (ECCO 14) - Barcelona, SPAIN Duration: 23 Sept 2007 → 27 Sept 2007

Access to Document

10.1016/S1359-6349(07)71298-3

Cite this

@article{bd3eaa98c62549568011953efaf2c11f,

title = "MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukaemia but can be preferentially targeted by the MDM2 inhibitor Nutlin-3a",

author = "I Tinhofer and I Gryshchenko and M Stoecher and Sebastian Hofbauer and PT Daniel and Richard Greil",

year = "2007",

doi = "10.1016/S1359-6349(07)71298-3",

language = "English",

volume = "5",

pages = "347--347",

journal = "ECJ SUPPLEMENTS",

issn = "1359-6349",

number = "4",

note = "14th European Cancer Conference (ECCO 14) ; Conference date: 23-09-2007 Through 27-09-2007",

}

TY - JOUR

T1 - MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukaemia but can be preferentially targeted by the MDM2 inhibitor Nutlin-3a

AU - Tinhofer, I

AU - Gryshchenko, I

AU - Stoecher, M

AU - Hofbauer, Sebastian

AU - Daniel, PT

AU - Greil, Richard

PY - 2007

Y1 - 2007

U2 - 10.1016/S1359-6349(07)71298-3

DO - 10.1016/S1359-6349(07)71298-3

M3 - Abstract (Journal)

SN - 1359-6349

VL - 5

SP - 347

EP - 347

JO - ECJ SUPPLEMENTS

JF - ECJ SUPPLEMENTS

IS - 4

T2 - 14th European Cancer Conference (ECCO 14)

Y2 - 23 September 2007 through 27 September 2007

ER -